{"DataElement":{"publicId":"6004368","version":"1","preferredName":"Adverse Event Correlation Type","preferredDefinition":"The causal relationship between a subject's participation in a study, including study-related therapy and procedures, and a specific adverse event. [Manually-curated]_Related to correlation between specified therapeutic procedure and adverse event","longName":"2635209v1.0:6004363v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2635209","version":"1","preferredName":"Adverse Event Research Attribution","preferredDefinition":"The causal relationship between a subject's participation in a study, including study-related therapy and procedures, and a specific adverse event. [Manually-curated]","longName":"AE_RSCH_ATTR","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"2235992","version":"1","preferredName":"Adverse Event","preferredDefinition":"Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure (attribution of unrelated, unlikely, possible, probable, or definite). The concept refers to events that could be medical product related, dose related, route related, patient related, caused by an interaction with another therapy or procedure, or caused by opioid initiation or dose escalation. The term also is referred to as an adverse experience. The old term Side Effect is retired and should not be used.","longName":"C41331","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adverse Event","conceptCode":"C41331","definition":"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9860F29-74E9-7421-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-15","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-15","modifiedBy":"ONEDATA","dateModified":"2005-06-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2635207","version":"1","preferredName":"Clinical or Research Activity Attribution","preferredDefinition":"No value exists.:assigning to a cause or source.","longName":"C16203:C25358","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical or Research Activity","conceptCode":"C16203","definition":"Any specific activity undertaken during the course of a clinical study or research protocol.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Attribution","conceptCode":"C25358","definition":"To assign to a cause or source.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F6C3800-9774-5F40-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2007-05-01","modifiedBy":"ONEDATA","dateModified":"2007-05-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2F6C3800-9785-5F40-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2007-05-01","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6004363","version":"1","preferredName":"Adverse Event Correlation Type","preferredDefinition":"Related to correlation between specified therapeutic procedure and adverse event","longName":"6004363v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Alt-803","valueDescription":"Superagonist Interleukin-15:Interleukin-15 Receptor alphaSu/Fc Fusion Complex ALT-803","ValueMeaning":{"publicId":"6004367","version":"1","preferredName":"Nogapendekin Alfa","longName":"6004367","preferredDefinition":"A fusion protein complex composed of a mutated form of the cytokine interleukin (IL)-15 (IL-15N72D) and a soluble, dimeric IL-15 receptor alpha (IL-15Ra) Fc fusion protein (IL-15Ra-Fc) (IL-15N72D/IL-15Ra-Fc), with potential antineoplastic activity. Upon administration, superagonist interleukin-15:interleukin-15 receptor alphaSu/Fc fusion complex ALT-803 binds to the IL-2/IL-15 receptor beta-common gamma chain (IL-2Rbetagamma) receptor on natural killer (NK) and CD8+ T lymphocytes, which activates and increases the levels of NK cells and memory CD8+(CD44high) T-cells. The memory T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation. By coupling IL-15 to IL15Ra-Fc, this agent has a prolonged drug half-life and shows an increased ability to bind IL-2Rbetagamma, which enhances its immune stimulatory activity as compared to IL-15 alone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nogapendekin Alfa","conceptCode":"C107503","definition":"A fusion protein complex composed of a mutated form of the cytokine interleukin (IL)-15 (IL-15N72D) and a soluble, dimeric IL-15 receptor alpha (IL-15Ra) Fc fusion protein (IL-15Ra-Fc) (IL-15N72D/IL-15Ra-Fc), with potential antineoplastic activity. Upon administration, superagonist interleukin-15:interleukin-15 receptor alphaSu/Fc fusion complex N-803 binds to the IL-2/IL-15 receptor beta-common gamma chain (IL-2Rbetagamma) receptor on natural killer (NK) and CD8+ T lymphocytes, which activates and increases the levels of NK cells and memory CD8+(CD44high) T-cells. The memory T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation. By coupling IL-15 to IL15Ra-Fc, this agent has a prolonged drug half-life and shows an increased ability to bind IL-2Rbetagamma, which enhances its immune stimulatory activity as compared to IL-15 alone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BAAA573-85ED-197B-E053-F662850A215E","latestVersionIndicator":"Yes","beginDate":"2017-10-16","endDate":null,"createdBy":"RODGERSC","dateCreated":"2017-10-16","modifiedBy":"KUMMEROA","dateModified":"2022-05-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BAAA573-8606-197B-E053-F662850A215E","beginDate":"2017-10-16","endDate":null,"createdBy":"RODGERSC","dateCreated":"2017-10-16","modifiedBy":"ONEDATA","dateModified":"2017-10-16","deletedIndicator":"No"},{"value":"Mel","valueDescription":"Melphalan","ValueMeaning":{"publicId":"2654276","version":"1","preferredName":"Melphalan","longName":"2654276","preferredDefinition":"An orally available phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melphalan","conceptCode":"C633","definition":"A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32CD72AB-9FA5-289C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-06-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BAAA573-861A-197B-E053-F662850A215E","beginDate":"2017-10-16","endDate":null,"createdBy":"RODGERSC","dateCreated":"2017-10-16","modifiedBy":"ONEDATA","dateModified":"2017-10-16","deletedIndicator":"No"},{"value":"Elo","valueDescription":"Elotuzumab","ValueMeaning":{"publicId":"5621728","version":"1","preferredName":"Elotuzumab","longName":"5621728","preferredDefinition":"A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Elotuzumab","conceptCode":"C66982","definition":"A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BC55-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BAAA573-862E-197B-E053-F662850A215E","beginDate":"2017-10-16","endDate":null,"createdBy":"RODGERSC","dateCreated":"2017-10-16","modifiedBy":"ONEDATA","dateModified":"2017-10-16","deletedIndicator":"No"},{"value":"ENK cells","valueDescription":"Natural Killer Cells","ValueMeaning":{"publicId":"3282598","version":"1","preferredName":"Natural Killer Cells","longName":"3282598","preferredDefinition":"Natural killer cells are cells that resemble large granular lymphocytes. They do not express markers of either T or B cell lineage. They are positive for CD16, CD56, and CD 94. These cells do possess Fc receptors for IgG and can kill target cells using antibody-dependent cell-mediated cytotoxicity. They can also use perforin to kill cells in the absence of antibody and killing may occur without previous sensitization.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Natural Killer Cells","conceptCode":"C0022688","definition":"Natural killer cells are cells that resemble large granular lymphocytes. They do not express markers of either T or B cell lineage. They are positive for CD16, CD56, and CD 94. These cells do possess Fc receptors for IgG and can kill target cells using antibody-dependent cell-mediated cytotoxicity. They can also use perforin to kill cells in the absence of antibody and killing may occur without previous sensitization.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD62BB37-8D07-4542-E040-BB89AD43796B","latestVersionIndicator":"Yes","beginDate":"2011-09-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BAAA573-8642-197B-E053-F662850A215E","beginDate":"2017-10-16","endDate":null,"createdBy":"RODGERSC","dateCreated":"2017-10-16","modifiedBy":"ONEDATA","dateModified":"2017-10-16","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6004365","version":"1","preferredName":"Therapeutic Procedure Adverse Event Correlation Type","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.:Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).:The degree to which two or more quantities or events are linearly associated, a statistical relation between two or more variables such that systematic changes in the value of one variable are accompanied by systematic changes in the others.:Something distinguishable as an identifiable class based on common qualities.","longName":"C49236:C41331:C48834:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Adverse Event","conceptCode":"C41331","definition":"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Correlation","conceptCode":"C48834","definition":"The degree to which two or more quantities or events are linearly associated, a statistical relation between two or more variables such that systematic changes in the value of one variable are accompanied by systematic changes in the others.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BAAA573-858C-197B-E053-F662850A215E","latestVersionIndicator":"Yes","beginDate":"2017-10-16","endDate":null,"createdBy":"RODGERSC","dateCreated":"2017-10-16","modifiedBy":"ONEDATA","dateModified":"2017-10-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BAACA54-7368-6289-E053-F662850A82C1","latestVersionIndicator":"Yes","beginDate":"2017-10-16","endDate":null,"createdBy":"RODGERSC","dateCreated":"2017-10-16","modifiedBy":"MAESKEB","dateModified":"2022-03-01","changeDescription":"created for UAMS cmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3029677","version":"1","longName":"UAMS Clinical Research","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812848","version":"1","longName":"UAMS New CDEs","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"AE related to","type":"Preferred Question Text","description":"AE related to","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BAB3894-5053-1CA7-E053-F662850A15A0","latestVersionIndicator":"Yes","beginDate":"2017-10-16","endDate":null,"createdBy":"RODGERSC","dateCreated":"2017-10-16","modifiedBy":"MAESKEB","dateModified":"2021-03-11","changeDescription":"created for UAMS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}